Mastering Clinical Challenges and Emerging Therapies in IBD 2018
In-Person Event
Jul 21, 2018
Chicago, Illinois, USA
OVERVIEW
Mastering Clinical Challenges and Emerging Therapies in IBD is organized by Imedex and will be held on Jul 21, 2018 at The Gwen, Chicago, Illinois, United States of America.
The target audience for this medical event is gastroenterologists, hospitalists, internal medicine specialists, and other healthcare professionals (physicians-in-training, nurses, pharmacists, physicians assistants, etc.) involved and/or interested in the therapeutic management of patients with IBD. This CME Conference has been approved for a maximum of 6.5 AMA PRA Category 1 Credits.
Course Objectives:
• Assess the mechanism of action and therapeutic potential of evolving treatments in IBD
• Evaluate strategies for sequencing therapeutics in the era of biologics, immunotherapies, and biosimilars
• Identify a personalized therapeutic approach to optimally manage complex cases of Crohn's disease
• Interpret pivotal clinical trial data and novel management strategies for integration into clinical practice
• Describe therapeutic strategies designed to prevent infections and extraintestinal manifestations in IBD
• Define the role of treat-to-target in IBD regimens designed to maximize the opportunity to achieve remission and avoid relapse
• Identify strategies to de-escalate therapy once remission is achieved in IBD
• Assess the emerging role of biosimilars in IBD therapy and their integration into current standards of care
Time: 08:00 to 17:00
Speakers: Aline Charabaty, MD, Russell D. Cohen, MD, FACG, Jean-Frederic Colombel, MD, Raymond K. Cross, Jr., MD, MS, Sushila Dalal, MD, Stephen B. Hanauer, MD, FACG, David P. Hudesman, MD, David T. Rubin, MD, FACG, Conference Chair
Additional details will be posted as soon as they are available.
The target audience for this medical event is gastroenterologists, hospitalists, internal medicine specialists, and other healthcare professionals (physicians-in-training, nurses, pharmacists, physicians assistants, etc.) involved and/or interested in the therapeutic management of patients with IBD. This CME Conference has been approved for a maximum of 6.5 AMA PRA Category 1 Credits.
Course Objectives:
• Assess the mechanism of action and therapeutic potential of evolving treatments in IBD
• Evaluate strategies for sequencing therapeutics in the era of biologics, immunotherapies, and biosimilars
• Identify a personalized therapeutic approach to optimally manage complex cases of Crohn's disease
• Interpret pivotal clinical trial data and novel management strategies for integration into clinical practice
• Describe therapeutic strategies designed to prevent infections and extraintestinal manifestations in IBD
• Define the role of treat-to-target in IBD regimens designed to maximize the opportunity to achieve remission and avoid relapse
• Identify strategies to de-escalate therapy once remission is achieved in IBD
• Assess the emerging role of biosimilars in IBD therapy and their integration into current standards of care
Time: 08:00 to 17:00
Speakers: Aline Charabaty, MD, Russell D. Cohen, MD, FACG, Jean-Frederic Colombel, MD, Raymond K. Cross, Jr., MD, MS, Sushila Dalal, MD, Stephen B. Hanauer, MD, FACG, David P. Hudesman, MD, David T. Rubin, MD, FACG, Conference Chair
Additional details will be posted as soon as they are available.
KEY DATES
21 Jul, 2018
Event Start Date
21 Jul, 2018
Event End Date
SPECIALITIES
GastroenterologySUGGESTED HOTELS
CONFERENCE VENUE
The GwenRELATED CONFERENCES & LIVE WEBINARS
Quick Links